key: cord-0844117-am1rz8gk
authors: Soldevila, Laura; Valerio-Sallent, Lluís; Roure, Sílvia; Pérez-Quílez, Olga; Àngel, Miquel; Miralles, Ramón; López-Muñoz, Israel; Estrada, Oriol; Vallès, Xavier
title: Drug exposure may have a substantial influence on COVID-19 prognosis among residents of long-term care facilities: an exploratory analysis
date: 2021-07-07
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.007
sha: 7fb3615007f7716808c488eb4ff84ded7199ddc1
doc_id: 844117
cord_uid: am1rz8gk

OBJECTIVES: To explore the association between drug exposure and SARS-CoV-2 prognosis among elderly living in long-term care facilities (LTC) DESIGN: We carried out a cross-sectional study among old people living in LTC which had a proven SARS-CoV-2 infection, including socio-demographic data, comorbidities and drug intake at the moment of the diagnosis. The study was focused on ACE2 inhibitors, ARA-II blockers, inhaled bronchodilators, oral corticoids, platelet antiaggregants, oral anti-coagulants, statins and Vitamin D. RESULTS: 1 306 individuals were included, with a mean age of 86.7 years and 72.3% were females. The case fatality rate was of 24.4%. Among the studied exposures platelet antiaggregant were the most prevalent (24.7%). After adjusting for propensity score, the intake of inhaled corticoids (OR 0.73; p=0.03), statins (OR 0.65; p=0.03) were found to be protective factors of death, whereas ACE2 inhibitor showed an almost significant association (OR 0.73, p=0.07). CONCLUSIONS: Considering the high prevalence of drug intake among elderly, drug exposure may be an important Covid-19 disease modifier in LTC residents and should be considered when exploring prognostic risk factors associated to Covid-19.

to the combination of optimal epidemiological conditions for the spread of SARS-CoV-2 in enclosed spaces crowded with a highly vulnerable population.

One feature of this population that has received scant attention in this connection is drug consumption. LTC residents tend to be poly-medicated, with some of them taking up to a dozen or more different drugs. 2 Such drugs commonly include a wide array of pharmaceutical principles, but also antihypertensives, bronchodilators, anti-inflammatories, psychiatric medication, anti-osteoporotic treatments, statins and oral anticoagulants, and platelet antiaggregants. To explore the relation between the prevalent types of medication in LTC facilities and COVID-19 prognosis, we carried out a crosssectional study among LTC residents with SARS-CoV-2 infection as confirmed by RT-PCR test during the first wave of the pandemic (March-June 2020). The study population has been described elsewhere. 3 We collected data on medication being consumed at the moment of the diagnosis from the clinical records of the LTC facility. Our focus was on those drugs that aroused most interest among clinicians, those for which evidence had been gathered previously and those with a plausible association with COVID-19 prognosis such as ACE2 inhibitors, ARA-II blockers, inhaled bronchodilators, oral corticoids, platelet antiaggregants, oral anti-coagulants, statins and Vitamin D.

Participants were tested against recovery or death after adjusting for Propensity 5 Score (PS) at day 15, day 30 and overall. PS included participant baseline clinical, autonomy and frailty scores and socio-demographic data.

Data on drug intake and follow-up were recorded for 1 306 individuals, which represents 58.8% of the SARS-CoV-2-infected population living in LTC facilities from our study area (N = 2 221) during the study period. The mean age Table 1 for detailed description). After PS adjustment we observed a protective association for inhaled corticoids (OR 0.52; 95%CI 0.3-0.9; p = 0.03), and statins (OR 0.65; 95%CI 0.4-0.9; p = 0.03), including a close to significant protective association with ACE2-antagonist intake (OR 0.73; 95%CI 0.5-1.0, p = 0.07) at 30-day mortality after Covid-19 diagnosis (see Table 2 ). We did not find evidence of interaction with other bronchodilators (long-acting β agonists and long-acting muscarinic antagonists), or between the drugs studied among individuals with concomitant treatment. 6 Notwithstanding that with our study design we cannot conclude a causal effect between drugs intake and clinical prognosis, our results are consistent with most of the previously published evidence that ACE-2 antagonists, statins and inhaled corticoids may have a protective effect against severe COVID-19, [4] [5] [6] but not anti-thrombotic therapy, oral corticoids, ARA-II blockers and Vitamin D in the dosages typically given to the elderly. The most noteworthy finding, due to their potential as preventive therapy against severe COVID-19, is the protective association of inhaled corticoids. A recently published clinical trial strongly suggests this positive effect with regard to complicated COVID-19 in the general population. 7 Considering the prevalence of drug intake and the high attack rates of the disease in the LTC population during the first wave of the pandemic, the fraction of prevented deaths attributable to consumption of these drugs may have been substantial. It is worth noting that the interaction between inhaled corticoids, ACE-2 antagonists and statins and Covid-19 is most probably mediated by their effect as inflammatory modulators, at the local level in alveolar epithelia (ACE-2 inhibitors and inhaled corticoids) or systemically (statins). Given that ageing is related to a more pro-inflammatory status 8 our observations may not be easily translated to the general population.

Furthermore, the protective effect of these drugs could be due to long-term intake having caused chronic changes in the tissues targeted (i.e. lower or higher expression of ACE-2 receptor in respiratory epithelia). However, further exploration of these effects among residential populations may provide a better understanding of the physiopathology of COVID-19 as well as some clues for future therapeutic or preventive drug targets. The most important conclusion from our findings and the previously collected evidence is that drug exposure 7 may be an important COVID-19 disease modifier in LTC residents and should be considered when exploring prognostic risk factors.

Our heartfelt gratitude to all nursing homes teams for facilitating the collection of information required for this study. The study do not had any specific source of funding. 

Mortality associated with COVID-19 outbreaks in care homes Mortality associated with COVID-19 outbreaks in care homes: early international evidence 2020. Article in LTCcovid.org, International Long-Term Care Policy Network

High-Risk Medication Use in Older Residents of Long-Term Care Facilities: Prevalence, Harms, and Strategies to Mitigate Risks and Enhance Use

Risk factors for mortality of residents in nursing homes with Covid-19: A retrospective cohort study

Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?

A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?

Potential role of statins in COVID-19

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets